Medicine and Health
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
M. Schuler, K. Cuppens, et al.
This study by Martin Schuler and colleagues reveals groundbreaking insights into preoperative nivolumab with or without relatlimab for non-small-cell lung cancer. With a remarkable 95% achieving curative resection and superior disease-free survival rates in the combination group, this research highlights the potential of immunotherapy in reshaping lung cancer treatment.
Related Publications
Explore these studies to deepen your understanding of the subject.
